Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience

References

• National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [Internet]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_Quick Reference_8.5x11.pdf
   Google Scholar
• Murphy MF, Wallington TB, Kelsey P, .; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001;113:24–31.
   PubMed Web of Science ®Google Scholar
• British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10–23.
   PubMed Web of Science ®Google Scholar
• Loeffler TM, Weber FW, Hausamen TU. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study. J Cancer Res Clin Oncol 1991;117(Suppl. 4):S125–S128.
   Google Scholar
• Skubitz KM, Hamdan H, Thompson RC Jr. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 199315;72:2963–2969.
   PubMed Web of Science ®Google Scholar
• Goren MP, McKenna LM, Goodman TL. Combined intravenous and oral mesna in outpatients treated with ifosfamide. Cancer Chemother Pharmacol 1997;40:371–375.
   PubMed Web of Science ®Google Scholar
• Zelcer S, Kellick M, Wexler LH, . The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. Pediatr Blood Cancer 2008;50:1176–1180.
   PubMed Web of Science ®Google Scholar
• Mahadeo KM, Santizo R, Baker L, . Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. Pediatr Blood Cancer 2010;55:1296–1299.
   PubMed Web of Science ®Google Scholar
• Gillis S, Dann EJ, Rund D. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hematol 1996;51:26–31.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Alimena G, Latagliata R, . Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. Haematologica 1999;84:814–819.
   PubMed Web of Science ®Google Scholar
• Savoie ML, Nevil TJ, Song KW, . Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol 2006;17:763–768.
   PubMed Web of Science ®Google Scholar
• Bakhshi S, Singh P, Swaroop C. Outpatient consolidation chemotherapy in pediatric acute myeloid leukemia: a retrospective analysis. Hematology 2009;14:255–260.
   PubMed Web of Science ®Google Scholar
• Møller T, Nielsen OJ, Welinder P, . Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia. Eur J Haematol 2010;84:316–322.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Vesole DH, Zhang M, . Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997;20:445–450.
   PubMed Web of Science ®Google Scholar
• Morabito F, Martino M, Stelitano C, . Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002;87:1192–1199.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Viola A, . Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma. Hematol J 2004;5:222–226.
   PubMedGoogle Scholar
• Kassar M, Medoff E, Seropian S, . Outpatient high-dose melphalan in multiple myeloma patients. Transfusion 2007;47:115–119.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Ansell SM, Dingli D, . Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008;83:1131–1138.
   PubMed Web of Science ®Google Scholar
• Seropian S, Nadkarni R, Jillella AP, . Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplant 1999;23:599–605.
   PubMed Web of Science ®Google Scholar
• Devizzi L, Guidetti A, Tarella C, . High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008;26:5175–5182.
   PubMed Web of Science ®Google Scholar
• Algara M, Valls A, Vivancos P, . Outpatient total body irradiation for bone marrow transplantation. Bone Marrow Transplant 1994;14:381–382.
   PubMed Web of Science ®Google Scholar
• Stiff P, Mumby P, Miler L, . Autologous hematopoietic stem cell transplants that utilize total body irradiation can safely be carried out entirely on an outpatient basis. Bone Marrow Transplant 2006;38:757–764.
   PubMed Web of Science ®Google Scholar
• Leger C, Sabloff M, McDiarmid S, . Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol 2006;85:723–729.
   PubMed Web of Science ®Google Scholar
• Farah RA, Aquino VM, Munoz LL, . Safety and cost-effectiveness of outpatient total body irradiation in pediatric patients undergoing stem cell transplantation. J Pediatr Hematol Oncol 1998;20: 319–321.
   PubMed Web of Science ®Google Scholar
• Bredeson C, Perry G, Martens C, . Outpatient total body irradiation as a component of a comprehensive outpatient transplant program. Bone Marrow Transplant 2002;29:667–671.
   PubMed Web of Science ®Google Scholar
• Cantú-Rodríguez OG, Jaime-Pérez JC, Gutiérrez-Aguirre CH, . Outpatient allografting using non-myeloablative conditioning: the Mexican experience. Bone Marrow Transplant 2007;40:119–123.
   PubMed Web of Science ®Google Scholar
• Petersen SL, Madsen HO, Ryder LP, . Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution. Br J Haematol 2004;125:225–231.
   PubMed Web of Science ®Google Scholar
• Paganini H, Gómez S, Ruvinsky S, . Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 2003;97:1775–1780.
   PubMed Web of Science ®Google Scholar
• Chisholm JC, Dommett R. The evolution towards ambulatory and day-case management of febrile neutropenia. Br J Haematol 2006;135:3–16.
   PubMed Web of Science ®Google Scholar
• Gupta A, Swaroop C, Agarwala S, . Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol 2009;31: 635–641.
   PubMed Web of Science ®Google Scholar
• Mullen CA, Petropoulos D, Roberts WM, . Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999;86:126–134.
   PubMed Web of Science ®Google Scholar
• Tan SS, Van Gils CW, Franken MG, . The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. Value Health 2010;13:712–719.
   PubMed Web of Science ®Google Scholar
• Meisenberg BR, Ferran K, Hollenbach K, . Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998;21:927–932.
   PubMed Web of Science ®Google Scholar
• Summers N, Dawe U, Stewart DA. A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant 2000;26:389–395.
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Vogelsang GB, Krumm S, . Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999;17:2811–2818.
   PubMed Web of Science ®Google Scholar
• Frey P, Stinson T, Siston A, . Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant 2002;30:741–748.
   PubMed Web of Science ®Google Scholar